Annovis Bio (ANVS) Change in Cash (2019 - 2026)
Annovis Bio (ANVS) posted Change in Cash of -$5.3 million for Q1 2026, down 225.14% sequentially from $4.2 million in Q4 2025, and down 145.47% YoY from $11.7 million in Q1 2025.
Annovis Bio (ANVS) Change in Cash (2019 - 2026) Analysis & Trends
Annovis Bio has reported Change in Cash for 8 years, with the latest figure at -$5.3 million in Q1 2026.
- Quarterly Change in Cash fell 145.47% year-over-year to -$5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.0 million (down 141.98% YoY) and the FY2025 annual result came in at $9.0 million, up 87.2% from the prior year.
- Change in Cash declined to -$5.3 million in Q1 2026 per ANVS's latest filing, from $4.2 million in the prior quarter.
- Over five years, Change in Cash peaked at $11.7 million in Q1 2025 and troughed at -$11.6 million in Q1 2023.
- A 5-year average of -$1.9 million and a median of -$2.6 million in 2024 frame the typical range for Change in Cash.
- The widest YoY moves for Change in Cash: up 546.35% in 2025, down 693.16% in 2025.
- Over 5 years, Change in Cash stood at -$3.6 million in 2022, then soared by 83.37% to -$600222.0 in 2023, then plunged by 247.32% to -$2.1 million in 2024, then jumped by 303.67% to $4.2 million in 2025, then tumbled by 225.14% to -$5.3 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered -$5.3 million, $4.2 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - | 4.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.31 Mn |
| Dec 31, 2025 | 4.25 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | -5.11 Mn |
| Mar 31, 2025 | 11.68 Mn |
| Dec 31, 2024 | -2.08 Mn |
| Sep 30, 2024 | 8.64 Mn |
| Jun 30, 2024 | 860,799.00 |
| Mar 31, 2024 | -2.62 Mn |
| Dec 31, 2023 | -600,222.00 |
| Sep 30, 2023 | -9.37 Mn |
| Jun 30, 2023 | -1.03 Mn |
| Mar 31, 2023 | -11.62 Mn |
| Dec 31, 2022 | -3.61 Mn |
| Sep 30, 2022 | -3.99 Mn |
| Jun 30, 2022 | -6.69 Mn |
| Mar 31, 2022 | -3.02 Mn |
| Dec 31, 2021 | -1.77 Mn |
| Sep 30, 2021 | -1.77 Mn |
| Jun 30, 2021 | 43.62 Mn |